These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 16955688

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Promising phase I results against new HIV target.
    Whelan J.
    Drug Discov Today; 2004 Oct 01; 9(19):823. PubMed ID: 15381130
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.
    Clin Ther; 2008 Oct 01; 30(10):1794-805. PubMed ID: 19014835
    [Abstract] [Full Text] [Related]

  • 10. New drugs.
    Pozniak A.
    J HIV Ther; 2008 Jun 01; 13(2):27-33. PubMed ID: 18953271
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
    Yebra G, Holguín A.
    Antivir Ther; 2008 Jun 01; 13(8):1083-5. PubMed ID: 19195334
    [Abstract] [Full Text] [Related]

  • 14. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
    Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.
    Retrovirology; 2011 Dec 07; 8():101. PubMed ID: 22151792
    [Abstract] [Full Text] [Related]

  • 15. The absorption, distribution, metabolism and elimination of bevirimat in rats.
    Bullock P, Larsen D, Press R, Wehrman T, Martin DE.
    Biopharm Drug Dispos; 2008 Oct 07; 29(7):396-405. PubMed ID: 18615840
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Study may point way forward for bevirimat.
    Proj Inf Perspect; 2008 Dec 07; (47):11. PubMed ID: 19227562
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection.
    Fletcher PS, Shattock RJ.
    Curr Opin Investig Drugs; 2008 Feb 07; 9(2):189-200. PubMed ID: 18246522
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.